Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
Summary
No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts.
Regions display no specific organization or delineate regional network for the ovarian management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit.
To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.
Study Design
Observational Model: Cohort, Time Perspective: Retrospective
Conditions
Ovarian Epithelial Cancer
Intervention
Patient with ovarian epithelial cancer
Location
Calvados registry
Caen
France
Status
Not yet recruiting
Source
Centre Leon Berard
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT02981901
- ClinicalTrials.gov processed this data on December 05, 2016
Published on BioPortfolio: 2016-12-05T17:23:21-0500
Clinical Trials
RATIONALE: Studying samples of exhaled breath from patients with ovarian epithelial cancer, polycystic ovarian syndrome, or endometriosis and from healthy participants in the laboratory ma...
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who hav...
Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill their tumor cells. Combining vaccine therapy with interferon gamma may be a mor...
Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
RATIONALE: Drugs such as thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating...
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
PubMed Articles
Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer.
MiR-595 has been demonstrated to be involved in tumorigenesis of several cancers. However, the clinical significance of miR-595 in epithelial ovarian cancer (EOC) remains unclear. The aim of this stud...
MiR-133b regulates the expression of CTGF in epithelial-mesenchymal transition of ovarian cancer.
To explore the role of miR-133b in ovarian cancer and to preliminarily elucidate the mechanism of miR-133b in epithelial-mesenchymal transition (EMT) of ovarian cancer.
Epithelial ovarian cancer (EOC) is a disease with a poor survival rate mostly due to its discovery in late stages. The aim of this study was to investigate the metabolomic profile of ovarian cancer wi...
Long non-coding RNAs MNX1-AS1(MNX1-AS1) has been proved to be associated with ovarian cancer proliferation and invasion. However, the clinical significance of MNX1-AS1 in epithelial ovarian cancer (EO...
MiR-630 promotes epithelial ovarian cancer proliferation and invasion via targeting KLF6.
MicroRNAs play critical roles in post-translational gene expression. The current study was to investigate the effects of miR-630 in epithelial ovarian cancer.
Medical and Biotech [MESH] Definitions
Hereditary Breast And Ovarian Cancer Syndrome
Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.
Topotecan
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Ovarian Failure, Premature
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
Primary Ovarian Insufficiency
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
Tumor Protein P73
A homolog of p53 TUMOR SUPPRESSOR PROTEIN that encodes full-length trans-activating and N-terminally-truncated (DeltaN) isoforms. Detection of splice variants and isoforms in the nervous system (human TELENCEPHALON, CHOROID PLEXUS; CEREBROSPINAL FLUID), embryonic tissue, human BREAST CANCER; OVARIAN CANCER, suggest roles in cellular differentiation.
